Matthias Treiber
Overview
Explore the profile of Matthias Treiber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiessner J, Orben F, Schafer A, Fricke L, Schneider G, Reichert M, et al.
Endosc Int Open
. 2024 Mar;
12(3):E361-E366.
PMID: 38464982
The prognosis for pancreatic cancer remains poor. Molecular diagnostics and customized therapies are becoming increasingly important in clinical routine. Patient-derived, predictive model systems such as organoids have the potential to...
2.
Grasmeier M, Weber S, Treiber M, Thaler M, Luppa P
Clin Chem Lab Med
. 2023 Feb;
61(7):1255-1265.
PMID: 36753693
Objectives: The therapeutic antibody infliximab (IFX) has improved the life quality of numerous autoinflammatory disease patients. However, IFX can trigger the generation of anti-drug antibodies (ADA), whose optimal evaluation and ...
3.
Schulz D, Heilmaier M, Phillip V, Treiber M, Mayr U, Lahmer T, et al.
Endoscopy
. 2022 Nov;
55(5):415-422.
PMID: 36323331
Background: Risk stratification and recommendation for surgery for intraductal papillary mucinous neoplasm (IPMN) are currently based on consensus guidelines. Risk stratification from presurgery histology is only potentially decisive owing to...
4.
Grasmeier M, Langmann A, Langmann P, Treiber M, Thaler M, Luppa P
Therap Adv Gastroenterol
. 2021 Aug;
14:17562848211037849.
PMID: 34434255
Background: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors...
5.
Gaitzsch E, Passerini V, Khatamzas E, Strobl C, Muenchhoff M, Scherer C, et al.
Hemasphere
. 2021 Jul;
5(7):e603.
PMID: 34235400
The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received...
6.
Wurstle S, Spinner C, Voit F, Hoffmann D, Hering S, Weidlich S, et al.
Infection
. 2021 May;
49(5):927-934.
PMID: 33970430
Purpose: To evaluate the diagnostic reliability and practicability of self-collected oropharyngeal swab samples for the detection of SARS-CoV-2 infection as self-sampling could enable broader testing availability and reduce both personal...
7.
Schneider J, Mijocevic H, Ulm K, Ulm B, Weidlich S, Wurstle S, et al.
Respir Res
. 2021 Apr;
22(1):119.
PMID: 33892720
Background: In the absence of PCR detection of SARS-CoV-2 RNA, accurate diagnosis of COVID-19 is challenging. Low-dose computed tomography (CT) detects pulmonary infiltrates with high sensitivity, but findings may be...
8.
Deschler S, Kager J, Erber J, Fricke L, Koyumdzhieva P, Georgieva A, et al.
Viruses
. 2021 Feb;
13(2).
PMID: 33546489
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprises mild courses of disease as well as progression to severe disease, characterised by lung...
9.
Rothe K, Feihl S, Schneider J, Wallnofer F, Wurst M, Lukas M, et al.
Eur J Clin Microbiol Infect Dis
. 2020 Nov;
40(4):859-869.
PMID: 33140176
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Bacterial co-infections are associated with unfavourable outcomes in respiratory viral infections; however,...
10.
Dommasch M, Gebhardt F, Protzer U, Werner A, Schuster E, Brakemeier C, et al.
Notf Rett Med
. 2020 Oct;
23(8):660.
PMID: 33100899
[This corrects the article DOI: 10.1007/s10049-020-00759-8.].